Cable Car Capital LP Buys Shares of 514,583 MAIA Biotechnology, Inc. $MAIA

Cable Car Capital LP bought a new stake in shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) in the 2nd quarter, Holdings Channel reports. The firm bought 514,583 shares of the company’s stock, valued at approximately $741,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Centric Wealth Management bought a new position in MAIA Biotechnology during the 2nd quarter valued at approximately $1,107,000. Solas Capital Management LLC bought a new stake in MAIA Biotechnology in the second quarter worth $4,364,000. Geode Capital Management LLC boosted its holdings in MAIA Biotechnology by 9.5% in the fourth quarter. Geode Capital Management LLC now owns 296,740 shares of the company’s stock worth $454,000 after acquiring an additional 25,684 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of MAIA Biotechnology in the fourth quarter worth $120,000. Finally, Marshall Wace LLP purchased a new stake in shares of MAIA Biotechnology in the second quarter worth $29,000. Hedge funds and other institutional investors own 5.65% of the company’s stock.

Insider Activity

In other news, CEO Vlad Vitoc bought 72,700 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was acquired at an average cost of $1.39 per share, with a total value of $101,053.00. Following the completion of the acquisition, the chief executive officer owned 976,121 shares of the company’s stock, valued at approximately $1,356,808.19. This represents a 8.05% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Stan Smith bought 75,000 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was purchased at an average price of $1.34 per share, for a total transaction of $100,500.00. Following the purchase, the director owned 1,519,178 shares of the company’s stock, valued at approximately $2,035,698.52. This represents a 5.19% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired 161,599 shares of company stock valued at $220,535 over the last ninety days. Corporate insiders own 19.81% of the company’s stock.

MAIA Biotechnology Price Performance

Shares of NYSEAMERICAN:MAIA opened at $1.41 on Wednesday. The business has a fifty day moving average price of $1.37 and a 200-day moving average price of $1.45. The company has a market capitalization of $85.77 million, a PE ratio of -2.27 and a beta of 0.24. MAIA Biotechnology, Inc. has a 1-year low of $0.87 and a 1-year high of $3.19.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, sell-side analysts anticipate that MAIA Biotechnology, Inc. will post -0.54 earnings per share for the current fiscal year.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical?stage biopharmaceutical company developing a proprietary platform for site?specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody?based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high?contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody?radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.